Skip to main content
Erschienen in: AIDS and Behavior 4/2018

27.10.2017 | Original Paper

Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data

verfasst von: Zoë Baker, Marjan Javanbakht, Stan Mierzwa, Craig Pavel, Michelle Lally, Gregory Zimet, Pamina Gorbach

Erschienen in: AIDS and Behavior | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Young men who have sex with men (YMSM) face a disproportionately high burden of HIV. Oral pre-exposure prophylaxis (PrEP) is effective in preventing HIV acquisition, but adherence to PrEP among YMSM may be inadequate. Medication adherence may be assessed via biomarkers, which are expensive and invasive, or via self-report through Audio Computer Assisted Self-Interview (ACASI), which may result in over-reporting of adherence. In this paper we assess the potential of a new method of self-report, the Interactive Questionnaire System (iQS), in validly estimating true adherence rates. PrEP adherence among 167 YMSM aged 15–23 was measured via dried blood spot (DBS), ACASI, and iQS twice over a 24-week study period. Both ACASI- and iQS-reported data revealed that over 40% of individuals self-reporting adequate PrEP adherence had DBS-estimated drug levels indicating inadequate adherence. Adjusted logistic repeated measures random intercept regression analyses indicated that younger YMSM had higher odds of over-reporting adherence than older YMSM—each 1 year increase in age was associated with 0.79 times the odds of over-reporting adherence (95% CI 0.63, 0.98; p value = 0.031), and being African American was associated with 3.22 times greater odds of over-reporting than non-African Americans (95% CI 1.51, 6.90; p-value = 0.0003). These results suggest that ACASI and iQS methods of self-report significantly overestimate true PrEP adherence rates among YMSM, and that the odds of over-reporting adherence may be affected by both age and race.
Literatur
3.
Zurück zum Zitat Black D, Gates G, Sanders S, Taylor L. Demographics of the gay and lesbian population in the United States: evidence from available systematic data sources. Demography. 2000;37(2):139–54.CrossRefPubMed Black D, Gates G, Sanders S, Taylor L. Demographics of the gay and lesbian population in the United States: evidence from available systematic data sources. Demography. 2000;37(2):139–54.CrossRefPubMed
5.
Zurück zum Zitat Mustanski BS, Newcomb ME, Bois SND, Garcia SC, Grov C. HIV in young men who have sex with men: a review of epidemiology, risk and protective factors, and interventions. J Sex Res. 2011;48(2–3):218–53.CrossRefPubMedPubMedCentral Mustanski BS, Newcomb ME, Bois SND, Garcia SC, Grov C. HIV in young men who have sex with men: a review of epidemiology, risk and protective factors, and interventions. J Sex Res. 2011;48(2–3):218–53.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV-1 prevention among heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV-1 prevention among heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed
10.
Zurück zum Zitat Celum C, Baeten J. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evidence and evolving questions. Curr Opin Infect Dis. 2012;25(1):51–7.CrossRefPubMedPubMedCentral Celum C, Baeten J. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evidence and evolving questions. Curr Opin Infect Dis. 2012;25(1):51–7.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2012;17(6):2162–72.CrossRef Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2012;17(6):2162–72.CrossRef
12.
Zurück zum Zitat Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among african women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among african women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Hosek S, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, et al. Project PrEPare (ATN082): the acceptability and feasibility of an HIV pre-exposure prophylaxis (PrEP) trial with young men who have sex with men (YMSM). J Acquir Immune Defic Syndr. 1999;. https://doi.org/10.1097/QAI.0b013e3182801081. Hosek S, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, et al. Project PrEPare (ATN082): the acceptability and feasibility of an HIV pre-exposure prophylaxis (PrEP) trial with young men who have sex with men (YMSM). J Acquir Immune Defic Syndr. 1999;. https://​doi.​org/​10.​1097/​QAI.​0b013e3182801081​.
14.
Zurück zum Zitat Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. JAIDS J Acquir Immune Defic Syndr. 2014;66(3):324–31.CrossRefPubMed Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. JAIDS J Acquir Immune Defic Syndr. 2014;66(3):324–31.CrossRefPubMed
15.
Zurück zum Zitat Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: Concordance with drug detection. J Acquir Immune Defic Syndr (1999). 2014;66(5):530–7.CrossRef Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: Concordance with drug detection. J Acquir Immune Defic Syndr (1999). 2014;66(5):530–7.CrossRef
16.
Zurück zum Zitat Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(suppl_1):S55–60.CrossRefPubMedPubMedCentral Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(suppl_1):S55–60.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Rudy B, Murphy D, Harris R, Muenz L, Ellen J. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDs. 2009;23:185–94.CrossRefPubMedPubMedCentral Rudy B, Murphy D, Harris R, Muenz L, Ellen J. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDs. 2009;23:185–94.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Hosek S, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, et al. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21–9.CrossRefPubMedPubMedCentral Hosek S, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, et al. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21–9.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Gorbach PM, Mensch BS, Husnik M, Coly A, Mâsse B, Makanani B, et al. Effect of computer-assisted interviewing on self-reported sexual behavior data in a microbicide clinical trial. AIDS Behav. 2012;17(2):790–800.CrossRef Gorbach PM, Mensch BS, Husnik M, Coly A, Mâsse B, Makanani B, et al. Effect of computer-assisted interviewing on self-reported sexual behavior data in a microbicide clinical trial. AIDS Behav. 2012;17(2):790–800.CrossRef
22.
Zurück zum Zitat Brener ND, Billy JOG, Grady WR. Assessment of factors affecting the validity of self-reported health-risk behavior among adolescents—assessment of factors affecting the validity.pdf. J Adolesc Health. 2003;33:436–57.CrossRefPubMed Brener ND, Billy JOG, Grady WR. Assessment of factors affecting the validity of self-reported health-risk behavior among adolescents—assessment of factors affecting the validity.pdf. J Adolesc Health. 2003;33:436–57.CrossRefPubMed
23.
Zurück zum Zitat Tangmunkongvorakul A, Chariyalertsak S, Amico KR, Saokhieo P, Wannalak V, Sangangamsakun T, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013;25(8):961–7.CrossRefPubMed Tangmunkongvorakul A, Chariyalertsak S, Amico KR, Saokhieo P, Wannalak V, Sangangamsakun T, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013;25(8):961–7.CrossRefPubMed
24.
Zurück zum Zitat Kennedy BR, Mathis CC, Woods AK. African Americans and their distrust of the health care system: healthcare for diverse populations. J Cult Divers. 2007;14(2):56–60.PubMed Kennedy BR, Mathis CC, Woods AK. African Americans and their distrust of the health care system: healthcare for diverse populations. J Cult Divers. 2007;14(2):56–60.PubMed
25.
Zurück zum Zitat Eiser A, Ellis G. Viewpoint: cultural competence and the African American experience with health care: the case for specific content in cross-cultural education. Acad Med. 2007;82(2):176–83.CrossRefPubMed Eiser A, Ellis G. Viewpoint: cultural competence and the African American experience with health care: the case for specific content in cross-cultural education. Acad Med. 2007;82(2):176–83.CrossRefPubMed
26.
Zurück zum Zitat Corbie-Smith G, Thomas S, George DMMS. Distrust, race, and research. Arch Intern Med. 2002;162(2):2458–63.CrossRefPubMed Corbie-Smith G, Thomas S, George DMMS. Distrust, race, and research. Arch Intern Med. 2002;162(2):2458–63.CrossRefPubMed
27.
Zurück zum Zitat Zheng J-H, Guida L, Rower C, Castillo-Mancilla JR, Meditz A, Klein B, et al. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC–MS/MS. J Pharm Biomed Anal. 2014;88(25):144–51.CrossRefPubMed Zheng J-H, Guida L, Rower C, Castillo-Mancilla JR, Meditz A, Klein B, et al. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC–MS/MS. J Pharm Biomed Anal. 2014;88(25):144–51.CrossRefPubMed
28.
Zurück zum Zitat Castillo-Mancilla JR, Zheng J-H, Rower JE, Meditz A, Gardner EM, Predhomme J, et al. Tenofovir, emtricitabine, and Tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2012;29(2):384–90.PubMed Castillo-Mancilla JR, Zheng J-H, Rower JE, Meditz A, Gardner EM, Predhomme J, et al. Tenofovir, emtricitabine, and Tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2012;29(2):384–90.PubMed
29.
Zurück zum Zitat Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2007;12(1):86–94.CrossRefPubMed Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2007;12(1):86–94.CrossRefPubMed
Metadaten
Titel
Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data
verfasst von
Zoë Baker
Marjan Javanbakht
Stan Mierzwa
Craig Pavel
Michelle Lally
Gregory Zimet
Pamina Gorbach
Publikationsdatum
27.10.2017
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 4/2018
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-1958-4

Weitere Artikel der Ausgabe 4/2018

AIDS and Behavior 4/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.